A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Summary

This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36 patients from the US will be enrolled in this study.

Timeline

Start

2009-03

Primary completion

2009-07

Completion

—

Drugs

Indications